Huntington’s disease (HD) affects children, adolescents, adults, and the elderly across the world. This is a progressive brain disorder that leads to emotional issues, loss of cognitive ability, and uncontrollable movements. Of the different age groups, adults (30–50 years) most-prominently show the symptoms and signs of this disease, as HD is the most common in this population group. Common early signs and symptoms include depression, poor coordination, irritability, minute involuntary movements, and trouble in decision making.
Thus, the presence of a large middle-aged population is expected to accelerate the Huntington’s disease genetic testing market growth at a CAGR of 3.1% between 2020 and 2030. According to the World Bank, the population of people within the age bracket of 15–64 years stood at 5.0 billion in 2019. Apart from this, the advancements in medical sciences are expected to increase the market size from $20.6 million in 2019 to $28.3 million by 2030, by allowing for more-advanced and affordable testing kits to make it to hospitals and diagnostic laboratories.
A large section of people is opting for HD genetic testing due to the growing awareness about the disease as a result of the initiatives taken by private and public organizations. This is being done owing to the increasing focus of researchers on developing novel technologies for testing. For example, on September 26, 2020, the University of Colorado, U.S., and the Huntington’s Disease Society of America (HDSA) organized the Annual Huntington’s Disease Family Education Day to generate awareness regarding the advantages of early disease diagnosis and management.
Get the sample pages of this report: https://www.psmarketresearch.com/market-analysis/huntingtons-disease-genetic-testing-market/report-sample
However, the lowering cost of genetic tests and surging prevalence of HD have majorly led to the increasing test volumes. At present, these tests cost between $100 and $200, depending on the complexity, nature, and count of the tests. Moreover, the wide availability of test kits across the globe has led to a stronger focus on the early diagnosis of HD. Besides, the high prevalence of HD in developed countries, such as Germany, the U.K., and the U.S., is leading to a high volume of genetic tests.
Moreover, the growing focus of biotechnology companies, institutes, and health organizations on the launch of genetic testing kits and tests has led to a surge in their accessibility in recent years. For instance, Asuragen Inc., in January 2019, announced the launch of the AmplideX PCR/CE HTT kit. This kit detects the aberrations related to HD — a repetition of cytosine–adenine–guanine (CAG) trinucleotide within the Huntington (HTT) gene. The HTT kit has widened the access to advanced testing methodology for the masses, which is expected to help in a more-effective diagnosis and better management of HD.
Geographically, the North American Huntington’s disease genetic testing market uses the largest number of testing kits, due to the growing cases of HD in the region and presence of industry giants in the U.S. Besides, the high healthcare expenditure and existence of an umpteen number of places where genetic testing is conducted will propel the demand for HD genetic testing kits in the region. Additionally, the booming geriatric population, escalating number of companies offering complete testing services, and augmenting research activities on genetic disorders in the U.S. are adding to the volume of these tests.
Thus, the large population of middle-aged people and low cost of genetic testing are fueling the adoption of the associated kits around the world.
